Understanding liver crises in sickle cell disease
Official title: Molecular Mechanism of Sickle Cell Hepatic Crisis
Funded at Versiti Wisconsin, INC. · NIH-11046709 · Data updated 2026-11-12
This study is looking into how sickle cell disease can harm the liver and cause serious problems, with the hope of finding new ways to help prevent these issues for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | July 15, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $147,139 |
| NIH project number | 5K01DK125617-06 |
| Project ID | NIH-11046709 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with sickle cell disease, particularly those who have experienced liver complications.
✕Less likely to help
Patients without sickle cell disease or those who have not experienced hepatic crises may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind liver crises that occur in patients with sickle cell disease (SCD). The study aims to identify how sickle cell disease leads to liver injury and cholestasis, which can be life-threatening. By utilizing advanced techniques and a humanized transgenic model, the research seeks to uncover the biological pathways involved in these complications. The findings could pave the way for new preventive therapies to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to better preventive treatments for liver crises in sickle cell disease patients.
How similar studies have gone: While the specific molecular mechanisms of hepatic crises in sickle cell disease are not well-studied, similar research approaches have shown promise in understanding other complications of sickle cell disease.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Pradhan-Sundd, Tirthadipa — Versiti Wisconsin, INC.
- Study coordinator: Pradhan-Sundd, Tirthadipa
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.